Zobrazeno 1 - 10
of 293
pro vyhledávání: '"Mark A Giembycz"'
Autor:
Rosalind L. Smyth
Publikováno v:
New England Journal of Medicine. 343:1661-1662
Publikováno v:
Allergy, Asthma & Clinical Immunology, Vol 14, Iss 1, Pp 1-14 (2018)
Abstract Background Asthma exacerbations are associated with the recruitment of neutrophils to the lungs. These cells release proteases and mediators, many of which act at G protein-coupled receptors (GPCRs) that couple via Gq to promote bronchoconst
Externí odkaz:
https://doaj.org/article/e786ff38724641e38062cc790aca28a9
Publikováno v:
British Journal of Pharmacology. 179:4593-4614
It has been proposed that genomic mechanisms contribute to adverse effects often experienced by asthmatic subjects who take regular, inhaled βGene expression changes were determined by RNA-sequencing. Gene silencing and genome editing were employed
Publikováno v:
Molecular Pharmacology. 100:388-405
Chronic use of β2-adrenoceptor agonists as a monotherapy in asthma is associated with a loss of disease control and an increased risk of mortality. Herein, we tested the hypothesis that β2-adrenoceptor agonists, including formoterol, promote biased
Autor:
Tresa George, Matthew Bell, Mainak Chakraborty, David P Siderovski, Mark A Giembycz, Robert Newton
Publikováno v:
PLoS ONE, Vol 12, Iss 1, p e0170269 (2017)
The GTPase-accelerating protein, regulator of G-protein signalling 2 (RGS2) reduces signalling from G-protein-coupled receptors (GPCRs) that signal via Gαq. In humans, RGS2 expression is up-regulated by inhaled corticosteroids (ICSs) and long-acting
Externí odkaz:
https://doaj.org/article/572fe8d91a2047e4a7e647fc646c4bf5
Autor:
Omar Hamed, Mark A. Giembycz
Publikováno v:
The FASEB Journal. 36
Autor:
Mark A. Giembycz, Richard Leigh, Robert Newton, Mahmoud M. Mostafa, Christopher F. Rider, N. Dulmini Wathugala
Publikováno v:
Molecular Pharmacology. 99:197-216
In 2019, the Global Initiative for Asthma treatment guidelines were updated to recommend that inhaled corticosteroid (ICS)/long-acting β 2-adrenoceptor agonist (LABA) combination therapy should be a first-in-line treatment option for asthma. Althoug
Autor:
Mahmoud M. Mostafa, Shahina Wiehler, Mark A. Giembycz, Aubrey N. Michi, Radhika Joshi, Dong Yan, Robert Newton, Omar Hamed
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 376:161-180
There is a clear, unmet clinical need to identify new drugs to treat individuals with asthma, chronic obstructive pulmonary disease (COPD), and idiopathic pulmonary fibrosis (IPF) in whom current medications are either inactive or suboptimal. In prec
Autor:
Mark A Giembycz, Stephen K Field
Publikováno v:
Drug Design, Development and Therapy, Vol 2010, Iss default, Pp 147-158 (2010)
Mark A Giembycz1, Stephen K Field2Departments of 1Physiology and Pharmacology and 2Medicine, Airway Inflammation Research Group, Faculty of Medicine, University of Calgary, Alberta, CanadaAbstract: In April 2010, the European Medicines Agency Committ
Externí odkaz:
https://doaj.org/article/ff76ce2c519e4a30a4bb00a345e0b3a9
Publikováno v:
PLoS ONE, Vol 10, Iss 1, p e0116773 (2015)
Acting on the glucocorticoid receptor (NR3C1), glucocorticoids are widely used to treat inflammatory diseases. However, glucocorticoid resistance often leads to suboptimal asthma control. Since glucocorticoid-induced gene expression contributes to gl
Externí odkaz:
https://doaj.org/article/75f36970dae643a6844edc1126f14280